About F-Star

We are an innovation focused biotech company dedicated to delivering next-generation multispecific antibody therapeutics so more people with cancer and other serious diseases can live longer and improved lives.

Our clinically validated multispecific antibody platform has delivered a deep proprietary and partnered pipeline of promising clinical and preclinical drug product candidates.

The “plug-and-play” format of our Fcab® and mAb technology platforms enables rapid discovery of differentiated drug product candidates with a natural human antibody format that allows for a straightforward manufacturing process, favourable safety profile and strong biological potency.

In 2023, F-star was acquired by invoX Pharma, a research-driven global biopharmaceutical company that uses next-generation technology platforms to discover and develop innovative medicines that can change the lives of people around the world.

Leadership

Our executive leadership team members have extensive experience in immuno-oncology and have worked with global pharmaceutical companies as well as biotechs, with a well-established track record of building biotech companies and developing biologics.

Neil Brewis

Executive Chairperson

Neil Brewis

Executive Chairperson

Over 25 years of experience in antibody engineering and drug R&D and has successfully advanced novel platforms from inception to clinical proof of concept, with a therapeutic focus in oncology. Formerly at GSK and Domantis Ltd.

Ryan Fiehler

Head of F-star Therapeutic Innovation

Ryan Fiehler

Head of F-star Therapeutic Innovation

Katy Everett

Head of Discovery

Katy Everett

Head of Discovery

Thomas Gallagher

Head of Data Science

Thomas Gallagher

Head of Data Science

Pauline Stevens

Head of Operations

Pauline Stevens

Head of Operations

Pharmaceutical Partnerships

F-star’s platform has been validated through partnerships for over a decade. We have collaboration and licensing agreements with many leading biopharma companies to research, develop, and commercialize therapies leveraging our modular antibody technology and mAb2 programs.  Our partners are targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS, among others.